α-1 antitrypsin PI MZ heterozygotes have reduced lung function in two large cohorts Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD Year: 2009
One year follow-up on pulmonary function for lobectomized patients. Source: International Congress 2017 – General thoracic surgery Year: 2017
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017 Year: 2017
Alpha-1-antitrypsin deficiency patients (AATD): two-year follow-up Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002
Early signs of COPD in 42 years old individuals with severe alpha-1-antitrypsin deficiency Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
SERPINA1 MS and MZ heterozygotes and lung function decline in the SAPALDIA cohort studySource: Annual Congress 2010 - Genetics of obstruction Year: 2010
Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017
Lung function at the age of 35 years in individuals with alpha-1-antitrypsin deficiency identified by neonatal screening Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
Lung disease caused by non-null ABCA3 mutations: long-term follow-up Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Study of pulmonary function in children with homozygous beta thalassemia Source: Eur Respir J 2002; 20: Suppl. 38, 140s Year: 2002
One year follow-up of intrabronchial lung volume reduction in alpha-1-antitrypsin deficiency and severe emphysema Source: Annual Congress 2011 - Treatment beyond inhalers: endoscopic lung volume reduction Year: 2011
Smoke exposure as a determinant of autoantibody titre in alpha 1-antitrypsin deficiency and COPD Source: Eur Respir J 2011; 37: 32-38 Year: 2011
1 year clinical follow-up of patients affected by acute pulmonary embolism (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 270s Year: 2005
5 year survival of patients with distal chronic thromoembolic pulmonary hypertension; comparison of treated patients with distal disease and residual disease post pulmonary endartectomy Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010
Prevalence of mutations in the alpha 1 antitrypsin gene in patients with pulmonary emphysema Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
Clinical, functional, radiologic and quality of life characteristics in PI*SZ Alpha 1-Antitrypsin Deficiency (AATD) compared to PI*ZZ, PI*MZ and COPD without AATD: a retrospective cohort study. Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021
Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006
Mortality of patients with emphysema and alpha-1-antitrypsin deficiency of Pi Z phenotype Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001
Knowledge of prognosis of chronic obstructive pulmonary disease (COPD) patients and their families in the last year of life Source: Eur Respir J 2002; 20: Suppl. 38, 205s Year: 2002
What makes Alpha1-antitrypsin deficiency patients exacerbate: a 5-year cohort Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021